Dr. Tezapsidis is the founder of Neurotez, Inc. and has been the President, Chief Executive Officer and Chairman of the Board of Directors since the company was incorporated in 2005. Nikolaos initially successfully raised seed funds primarily through non-dilutive capital sources ($5mill) while building the company, recruiting top talent, maintaining top notch research and development programs and establishing a strong patent portfolio. He later closed a milestone-linked $100 million deal exclusive for China, which eventually was cancelled. He initiated a couple of partnerships, one for a new memory screening test for Alzheimer’s patients with Memtrax and two with Cytox for a polygenic test that renders a score for genetic risk for Alzheimer’s disease, both crucial for patient recruitment and drug efficacy monitoring in clinical trials. Currently Neurotez has received a $50 million equity line offer from a prominent alternative investment group and is negotiating a bridge facility to enable transitioning to a publicly listed company in the US. Clinical trials are expected to begin within the next 12 months following manufacturing of the biologic drug in India and application of an IND application in the US.
Among his career honors he received two awards from the Alzheimer’s Association, USA and fellowships from the Wellcome Trust and the Science and Engineering Council, UK. He has several patents issued and pending both in the US and in foreign markets and is the author of more than fifty publications.
Dr. Tezapsidis received a Bachelor of Science in Chemistry from the Aristotle University, Greece and completed his Master of Science and Doctor of Philosophy in Biochemistry at the University of Sussex, UK.